Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $63.00 to $65.00. They now have an "outperform" rating on the stock.
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements